Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Exclusion Criteria

• •1. Currently have non plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis.
• •2. 3\. Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.
• •3. Have received any of the following treatment regimens specified in the timeframes outlined below:
• •Within 9 months of first dose of study drug:
• •Ustekinumab (Stelara).
• •Within 12 weeks of first dose of study drug:
• •Any experimental therapy for psoriasis or rheumatoid arthritis.
• •Within 4 8 weeks of first dose of study drug:
• •Biologic therapies for psoriasis have discontinuation periods determined from approximately 5x half life of the respective biologic:
• •4 weeks: etanercept (Enbrel).
• •8 weeks: infliximab (Remicade), adalimumab (Humira).
• •Within 4 weeks of first dose of study drug:
• •Systemic treatments other than biologics that could affect psoriasis (eg, oral or injectable corticosteroids, retinoids, methotrexate, cyclosporine, fumaric acid derivatives, sulfasalazine, hydroxycarbamide (hydroxyurea), azathioprine).
• •Phototherapy and psoralen plus ultraviolet A therapy (PUVA).
• •Other - intramuscular gold, immunization with any live virus vaccination (eg, FluMist), herbal medications.
• •Within 2 weeks of first dose of study drug:
• •Topical treatments that could affect psoriasis (eg, corticosteroids, tars, keratolytics, anthralin, vitamin D analogs, and retinoids).
• •Phototherapy with ultraviolet B (UVB) (narrowband or broadband).